Recent advances in canine leptospirosis: focus on vaccine development

Henricus LBM (Eric) Klaasen,1 Ben Adler2 1Global Companion Animals Research and Development, Merck Sharp and Dohme Animal Health, Boxmeer, the Netherlands; 2Department of Microbiology, Monash University, Clayton, VIC, Australia Abstract: Leptospirosis is a global infection of humans and animals cau...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Klaasen HLBM, Adler B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/3e49cb3e01bf4938a1fa58acb6676367
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e49cb3e01bf4938a1fa58acb6676367
record_format	dspace
spelling	oai:doaj.org-article:3e49cb3e01bf4938a1fa58acb66763672021-12-02T06:18:50ZRecent advances in canine leptospirosis: focus on vaccine development2230-2034https://doaj.org/article/3e49cb3e01bf4938a1fa58acb66763672015-06-01T00:00:00Zhttp://www.dovepress.com/recent-advances-in-canine-leptospirosis-focus-on-vaccine-development-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034Henricus LBM (Eric) Klaasen,1 Ben Adler2 1Global Companion Animals Research and Development, Merck Sharp and Dohme Animal Health, Boxmeer, the Netherlands; 2Department of Microbiology, Monash University, Clayton, VIC, Australia Abstract: Leptospirosis is a global infection of humans and animals caused by pathogenic Leptospira spp. Leptospirosis is a major zoonosis, with infection acquired from wild and domestic animals. It is also a significant cause of morbidity, mortality, and economic loss in production and companion animals. Leptospirosis in dogs is prevalent worldwide and as well as a cause of canine disease, it presents a zoonotic risk to human contacts. Canine leptospirosis does not differ greatly from the syndromes seen in other animal species, with hepatic, renal, and pulmonary involvement being the main manifestations. While the pathogenesis of disease is well documented at the whole animal level, the cellular and molecular basis remains obscure. Killed, whole-cell bacterin vaccines are licensed worldwide and have not changed greatly over the past several decades. Vaccine-induced immunity is restricted to serologically related serovars and is generally short-lived, necessitating annual revaccination. The appearance of new serovars as causes of canine leptospirosis requires constant epidemiological surveillance and tailoring of vaccines to cover emerging serovars. At the present time, there is no realistic prospect of alternative, non-bacterin vaccines in the foreseeable future. Keywords: canine leptospirosis, vaccines, diagnosis, epidemiology, pathogenesisKlaasen HLBMAdler BDove Medical PressarticleVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol 2015, Iss default, Pp 245-260 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Veterinary medicine SF600-1100
spellingShingle	Veterinary medicine SF600-1100 Klaasen HLBM Adler B Recent advances in canine leptospirosis: focus on vaccine development
description	Henricus LBM (Eric) Klaasen,1 Ben Adler2 1Global Companion Animals Research and Development, Merck Sharp and Dohme Animal Health, Boxmeer, the Netherlands; 2Department of Microbiology, Monash University, Clayton, VIC, Australia Abstract: Leptospirosis is a global infection of humans and animals caused by pathogenic Leptospira spp. Leptospirosis is a major zoonosis, with infection acquired from wild and domestic animals. It is also a significant cause of morbidity, mortality, and economic loss in production and companion animals. Leptospirosis in dogs is prevalent worldwide and as well as a cause of canine disease, it presents a zoonotic risk to human contacts. Canine leptospirosis does not differ greatly from the syndromes seen in other animal species, with hepatic, renal, and pulmonary involvement being the main manifestations. While the pathogenesis of disease is well documented at the whole animal level, the cellular and molecular basis remains obscure. Killed, whole-cell bacterin vaccines are licensed worldwide and have not changed greatly over the past several decades. Vaccine-induced immunity is restricted to serologically related serovars and is generally short-lived, necessitating annual revaccination. The appearance of new serovars as causes of canine leptospirosis requires constant epidemiological surveillance and tailoring of vaccines to cover emerging serovars. At the present time, there is no realistic prospect of alternative, non-bacterin vaccines in the foreseeable future. Keywords: canine leptospirosis, vaccines, diagnosis, epidemiology, pathogenesis
format	article
author	Klaasen HLBM Adler B
author_facet	Klaasen HLBM Adler B
author_sort	Klaasen HLBM
title	Recent advances in canine leptospirosis: focus on vaccine development
title_short	Recent advances in canine leptospirosis: focus on vaccine development
title_full	Recent advances in canine leptospirosis: focus on vaccine development
title_fullStr	Recent advances in canine leptospirosis: focus on vaccine development
title_full_unstemmed	Recent advances in canine leptospirosis: focus on vaccine development
title_sort	recent advances in canine leptospirosis: focus on vaccine development
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3e49cb3e01bf4938a1fa58acb6676367
work_keys_str_mv	AT klaasenhlbm recentadvancesincanineleptospirosisfocusonvaccinedevelopment AT adlerb recentadvancesincanineleptospirosisfocusonvaccinedevelopment
_version_	1718399985598332928

Recent advances in canine leptospirosis: focus on vaccine development

Ejemplares similares